Assembly Biosciences Executive Compensation (FY25)
ASMB · Executive and director compensation, fiscal 2025 only
The paid brief on Assembly Biosciences
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): June 5, 2026
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
112 figures on this page: 110 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
More on Assembly Biosciences
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
Frequently asked questions
Answers drawn from the data on this page.
Who is Assembly Biosciences' chief executive and what were they paid?
Jason Okazaki, Chief Executive Officer and President, received $2,482,987 in total compensation for fiscal 2025.
What was Assembly Biosciences' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 100.0% of votes cast for or against in favor at the meeting held June 4, 2026.
Which companies are in Assembly Biosciences' peer group?
Companies named in the disclosed peer group include Adverum Biotechnologies, Inc., Aligos Therapeutics, Inc., AN2 Therapeutics, Inc., Arbutus Biopharma Corporation and Atea Pharmaceuticals, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jason Okazaki Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
William Delaney Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Anuj Gaggar Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Anuj Gaggar | OPTION | — | — | — | — | — | — | ◇ |
| Anuj Gaggar | RSU | — | — | — | — | — | — | ◇ |
| Jason Okazaki | RSU | — | — | — | — | — | — | ◇ |
| Jason Okazaki | OPTION | — | — | — | — | — | — | ◇ |
| William Delaney | OPTION | — | — | — | — | — | — | ◇ |
| William Delaney | RSU | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| William Delaney | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Anuj Gaggar | Option | ◇ | — | ◇ | — |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Jason Okazaki | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Anuj Gaggar
Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
William Delaney
Chief Scientific Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Equity acceleration on change in control | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
William R. Ringo, Jr Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Anthony E. Altig | ◇ | — | ◇ | — | — | — | ◇ |
Susan Mahony, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Gina Consylman | ◇ | — | ◇ | — | — | — | ◇ |
John G. McHutchison, A.O., M.D | ◇ | — | ◇ | — | — | — | ◇ |
Lisa R. Johnson-Pratt, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Sir Michael Houghton, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Robert D. Cook II, Tomas Cihlar, Ph.D and Jason A. Okazaki served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Adverum Biotechnologies, Inc. ADVM
- Aligos Therapeutics, Inc. symbol not shown
- AN2 Therapeutics, Inc. ANTX
- Arbutus Biopharma Corporation ABUS
- Atea Pharmaceuticals, Inc. AVIR
- aTyr Pharma, Inc. ATYR
- Black Diamond Therapeutics, Inc. BDTX
- Caribou Biosciences, Inc. CRBU
- CytomX Therapeutics, Inc. CTMX
- Enanta Pharmaceuticals, Inc. ENTA
- Gossamer Bio, Inc. GOSS
- Hookipa Pharma Inc. HOOK
- Invivyd, Inc. IVVD
- Kronos Bio, Inc. symbol not shown
- Precision Biosciences, Inc. DTIL
- Spero Therapeutics, Inc. symbol not shown
- Terns Pharmaceuticals, Inc. TERN
- Vaxart, Inc. symbol not shown
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 4, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 5, 2025 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Assembly Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Assembly Biosciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
112 figures on this page: 110 cited to the filing that reported them, 2 calculated from figures it prints.
110 cited to the filing
2 calculated from the filing
Documents cited
- 0001193125-26-259481Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-170417Compensation Discussion and Analysis · Director Compensation · Outstanding Equity Awards at December 31, 2025 · Summary Compensation Table · and 1 more section
- 0000950170-25-083830Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Assembly Biosciences executive compensation, FY2025.” https://intel.velarion.ai/comp/ASMB (accessed 2026).
Short form: data: Velarion
The paid brief for Assembly Biosciences
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Assembly Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Assembly Biosciences discloses
The companies named in ASMB's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}